Page 87 - NATIONAL INSTITUTES OF HEALTH (NIH) GUIDELINES FOR CONDUCTING RESEARCH IN MINISTRY OF HEALTH (MOH) INSTITUTIONS & FACILITIES 3RD EDITION 2021

IMR INSTITUTIONAL BIOSAFETY & BIOSECURITY COMMITTEE (IMR IBBC)
PRELIMINARY ASSESSMENT FORM

INSTITUTE FOR MEDICAL RESEARCH MALAYSIA
Email: ibbcsecretariat@moh.gov.my

6. Brief summary of the project
(including objectives and
expected outcome):
(300 – 500 words)

7. Name(s) of infectious or
potentially infectious
agent/material or biological toxin
to be used in the study:
(eg: SARS-CoV-2, dengue,
diphtheria)

7a. Risk group of agent/ material or
toxin (refer to *Act 342- seventh 1 2 3 4 Unknown
Schedule, WHO, OIE)
7b. Risk group of agent/material or
toxin (refer to Plant Quarantine
Act 1976) – if relevant
7c. Risk assesment Evaluation Yes No
7d. Involve modern biotechnology Yes No
techniques in LMO / GMO agent
If yes :

State the recipient (s) :

State the donor (s) :

Note:
Please email the complete document to ibbcsecretariat@moh.gov.my within 14 working days from
notifiaction date.
IMR/IBBC/01
Version : 1.0
Date : 20.05.2021 Page 2 of 3

NIH Guidelines for Conducting Research in MOH, 2021 71